Barcode Alzheimer Biomarkers with Barcoded Magnetic Beads

使用条形码磁珠对阿尔茨海默病生物标记物进行条形码

• 批准号: 8464474
• 负责人: Winston Z. Ho
• 金额: $ 12.09万
• 依托单位: APPLIED BIOCODE, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8464474
• 关键词: Affinity; Alzheimer' s Disease; Amendment; Antibodies; Biological Assay; Biological Markers; Cerebrospinal Fluid; Clinical; Clinical Trials; Dementia; Development; Diagnosis; Diagnostic; Disease; Disease Progression; Dose; Early Diagnosis; Evaluation; Face; Feasibility Studies; Functional disorder; Growth Factor; Hormones; Immunoassay; Individual; Institution; Kinetics; Laboratories; Lead; Ligands; Lipids; Magnetic Bead Technology; Measures; Mechanics; Metabolic; Methodology; Methods; Monitor; Monoclonal Antibodies; Mus; Nature; Oryctolagus cuniculus; Patients; Performance; Phase; Phycoerythrin; Plasma; Protein Analysis; Proteins; Proteomics; Psyche structure; Qualifying; Reaction; Reading; Recovery; Reference Standards; Reporter; Research; Research Personnel; Running; Sampling; Screening procedure; Series; Signal Transduction; Solid; Solutions; Specificity; Spottings; Staging; Streptavidin; Supermarket; Technology; Testing; Time; Validation; Work; abstracting; analog; base; biochip; chemokine; cohort; cost; cost effective; cross reactivity; cytokine; design; digital; drug development; flexibility; inflammatory marker; instrument; magnetic beads; mild neurocognitive impairment; neuroimaging; optical imaging; pre-clinical; prognostic; protein profiling; success; tau Proteins; tool; treatment effect

DESCRIPTION (provided by applicant): Barcode Alzheimer Biomarkers with Barcoded Magnetic Beads Abstract: Current diagnosis of Alzheimer's relies largely on documenting mental decline. The tau and Ab42 have proven useful for predicting clinical progression in individuals who have very mild dementia or mild cognitive impairment. Nevertheless, even for these analytes, there is substantial overlap between control and AD groups, and a need for better prognostic ability. Given the multifactorial nature of AD pathophysiology, it is likely that there will be other biomarkers that will be useful in this regard. Alzheimer's Disease Neuroimaging Initiative (ADNI) uses targeted multiplex proteomic strategies to identify plasma-based biomarkers in Alzheimer's Disease (AD). While proteomic screens have identified a number of other candidate AD biomarkers, few studies have utilized large, well-characterized cohorts or have looked for biomarkers in preclinical or very early stage disease. While a great deal of works has been done, unfortunately, searching for biomarkers from a large number of protein profiling is still a daunting challenge. The current methods are labor intensive, high cost poor sensitivity, and have large CV. Moreover, one challenge researchers always face is that analysis of protein levels in the same sample often varies significantly from institution to institution. Current biomarker discovery technologies based on multiplex immunoassay are: 1. Microarray biochip: It has poor mechanical spotting repeatability, no content (target add-on) flexibility, poor reaction kinetics, low sensitivity, and not quantitative. 2. Bead based flow cytometer: It is not quantitative, has large CV (15 percent - 30 percent), limited sensitivity, beas carried over, and currently each panel only cover limited analytes. Applied BioCode, Inc. proposes to barcode all potential Alzheimer Disease Biomarkers with Barcoded Magnetic Beads (AD-BMB), which will provide the "high multiplicity", "high sensitivity", and "high accuracy" for al-in-one or many-in-one biomarkers screening and identification. Barcoded Magnetic Beads (BMB) utilize digital technology instead of conventional analog methodology, offering unmatched multiplexing capability, content flexibility, decoding accuracy and excellent sensitivity. More importantly, the analyzer is easy to use, robust, and will provide consistent and accurate results. Experts believe that biomarkers offer one of the most promising paths as reliable predictors and indicators of Alzheimer disease. PUBLIC HEALTH RELEVANCE: The resulting AD-BMB technology will offer an efficient, cost-effective, cerebrospinal fluid (CSF) or plasma- based multiplex assay platform to identify Alzheimer biomarkers, making it a potent diagnostic tool as predictors and indicators of AD. In addition to the Alzheimer application, the AD-BMB technology has a wide variety of applications in the biomedical and bioscience research fields.

描述（由申请人提供）：带有条形码磁珠的阿尔茨海默氏症生物标志物条形码摘要：目前阿尔茨海默氏症的诊断很大程度上依赖于记录精神衰退。事实证明，tau 蛋白和 Ab42 可用于预测患有极轻度痴呆或轻度认知障碍的个体的临床进展。然而，即使对于这些分析物，对照组和 AD 组之间也存在大量重叠，并且需要更好的预后能力。鉴于 AD 病理生理学的多因素性质，很可能 在这方面还有其他有用的生物标志物。阿尔茨海默病神经影像计划 (ADNI) 使用靶向多重蛋白质组学策略来识别阿尔茨海默病 (AD) 中基于血浆的生物标志物。虽然蛋白质组学筛选已经确定了许多其他候选 AD 生物标志物，但很少有研究利用大型、特征明确的队列或寻找临床前或非常早期疾病的生物标志物。不幸的是，尽管已经做了大量工作，但从大量蛋白质分析中寻找生物标志物仍然是一项艰巨的挑战。目前的方法劳动强度大、成本高、灵敏度差、CV大。此外，研究人员经常面临的一个挑战是，同一样本中蛋白质水平的分析往往因机构而异。目前基于多重免疫分析的生物标志物发现技术有： 1.微阵列生物芯片：机械点样重复性差，无内容（靶点附加）灵活性，反应动力学差，灵敏度低，不定量。 2.基于Bead的流式细胞仪：它不是定量的，CV较大（15% - 30%），灵敏度有限，beas遗留，目前每个面板仅覆盖有限的分析物。 Applied BioCode, Inc. 提议使用条形码磁珠 (AD-BMB) 对所有潜在的阿尔茨海默病生物标志物进行条形码标记，这将为一体机或多人提供“高多样性”、“高灵敏度”和“高精度”一体化生物标志物筛选和鉴定。条形码磁珠 (BMB) 采用数字技术而不是传统的模拟方法，提供无与伦比的复用能力、内容灵活性、解码准确性和出色的灵敏度。更重要的是，该分析仪易于使用、坚固耐用，并且能够提供一致且可靠的结果。 准确的结果。专家认为，生物标志物作为阿尔茨海默病的可靠预测因子和指标提供了最有前途的途径之一。 公共健康相关性：由此产生的 AD-BMB 技术将提供一种高效、经济的基于脑脊液 (CSF) 或血浆的多重检测平台来识别阿尔茨海默病生物标志物，使其成为作为 AD 预测因子和指标的有效诊断工具。 除了阿尔茨海默病应用外，AD-BMB技术在生物医学和生物科学研究领域也有广泛的应用。